Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Maintenance Therapy with N-803 after CD19 CAR T-cell Therapy for the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, CARMEN-803 Trial

Trial Status: approved

This phase I trial tests the safety, side effects, and best dose of N-803 as maintenance therapy after CD19 chimeric antigen receptor (CAR) T-cell therapy for the treatment of B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). N-803 is a protein complex that stimulates the growth, activation and cancer-killing activity of immune cells and causes the production of immune-related proteins called cytokines, which also leads to the death of cancer cells. Maintenance therapy with N-803 may improve the efficacy of treatment with CD19 CAR T-cell therapy by increasing CD19 CAR T-cell persistence and activation.